• Recent
  • Class
  • Inventors
  • Assignees
  • Top Lists
  • Pricing
  • Account
Patents-Review.com
  1. Home
  2. Inventor
  3. G
  4. Git…
  5. GITZINGER Marc
🔗 Permalink
Inventor profile of:

Marc GITZINGER

City:

Basel

Country:

Switzerland

Published Applications:

7

Last publication date:

2026-04-09

Recent patent applications by GITZINGER Marc

Marc GITZINGER from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-09
US20260098046A1
Chemistry; metallurgy

RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE

#2 | 2025-12-11
US20250376472A1
Chemistry; metallurgy

3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES

#3 | 2025-11-27
US20250360114A1
Human necessities

INTRAVENOUS RIFABUTIN FORMULATION AND METHODS OF MAKING

#4 | 2025-07-24
US20250235434A1
Human necessities

RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE

#5 | 2025-07-03
US20250213575A1
Human necessities

8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS

#6 | 2025-03-27
US20250101039A1
Chemistry; metallurgy

RIFAMYCIN DERIVATIVES FOR THE TREATMENT OF DISEASES

#7 | 2025-02-13
US20250051356A1
Chemistry; metallurgy

RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE

InventorID:

6927618 ⎘

  1. Home
  2. Inventor
  3. G
  4. Git…
  5. GITZINGER Marc

Some parts © 2022-2026 Patents-Review.com

Browse & Discovery
  • Home
  • Patent Classification
  • Inventor Index
  • Assignee Index
  • Interesting Applications
Search & Tools
  • Basic Search
  • Advanced Search
  • Patent Alerts
  • Top Lists
  • Statistics
Information & Resources
  • About US Patent System
  • Terms & Privacy
  • Pricing
  • Contact
Quick Access
  • Latest Applications
  • Top Inventors 2026
  • Top Assignees 2026
  • Featured Patents
Disclaimer: This website is intended for informational purposes only, and its content is based on public patent records. Please note that some sections of this website have been created or processed using machine learning models. We provide content in good faith but make no guarantees regarding accuracy or completeness. By using this site, you accept any risks and waive claims against us for errors or omissions.